### Guideline Page and Request

#### NSCL-3/NSCL-6/NSCL-7/NSCL-H/DIAG-A

- **Internal request:** Review the publication supporting osimertinib in the adjuvant setting.
- **External request:** Submission from AstraZeneca, requesting the addition of molecular testing for EGFR mutation to be performed on diagnostic biopsy or post-surgical resection sample to ensure the EGFR mutation results are available for adjuvant treatment decisions. Consider footnote addition for molecular testing recommendation for EGFR mutation on surgical resection sample to ensure EGFR mutation results are available for adjuvant treatment decisions in Stages IB–IIIA.

#### NSCL-4/NSCL-E

- **Internal request:** Review the publication supporting osimertinib in the adjuvant setting.
- **External request:** Submission from AstraZeneca, requesting osimertinib as an adjuvant treatment therapy option in patients with Stage IB–IIIA nonsquamous epidermal growth factor receptor mutation (EGFRm) positive NSCLC with complete tumor resection.

### Panel Discussion/References

Based upon review of the data in the noted references, the panel consensus supported the following changes:

- **NSCL-3, NSCL-6, NSCL-7**
  - Footnote q added: Consider testing for EGFR mutation on surgical tissue or biopsy in stages IB–IIIA.
  - See Submission for references.

- **NSCL-4**
  - Stage IB–IIIA, negative margins: Consider osimertinib added as a treatment option.
  - Footnote w added: For patients with EGFR mutation-positive NSCLC who received previous adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy.
  - NSCL-E
  - The following section added: Previous Adjuvant Chemotherapy or Ineligible for Platinum-Based Chemotherapy
    - Osimertinib 80 mg daily
    - Consider osimertinib for patients with completely resected Stage IB–IIIA EGFR mutation-positive NSCLC who received previous adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy.
  - See Submission for references.

### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>0</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Guideline Page and Request</td>
<td>Panel Discussion/References</td>
<td>Institution Vote</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td></td>
</tr>
</tbody>
</table>
| **NSCL-23**<br>External request: Submission from Takeda, requesting the listing of brigatinib as preferred in the first-line setting for patient with ALK rearrangement positive NSCLC. | The Panel consensus supported the listing of brigatinib as a preferred first-line therapy option for patients with an ALK rearrangement discovered prior to first-line systemic therapy.  
  - See Submission for references. | YES NO ABSTAIN ABSENT |
| **NSCL-31**<br>Internal request: Review the publication supporting atezolizumab in the metastatic setting.<br>External request: Submission from Genentech, requesting changing atezolizumab monotherapy to a category 1, preferred option for first-line therapy in patients with PD-L1 expression positive (≥ 50%) advanced or metastatic NSCLC. | Based upon review of the data in the noted references, the panel consensus supported changing atezolizumab to category 1 recommendation from a category 2A as first-line therapy in patients with PD-L1 expression positive (≥ 50%) advanced or metastatic NSCLC.  
  - See Submission for references. | 22 0 1 8 |